![]() |
市場調查報告書
商品編碼
1422916
2024-2032 年按類型、年齡層、配銷通路、應用、最終用途和地區分類的黏稠補充劑市場Viscosupplementation Market by Type, Age Group, Distribution Channel, Application, End Use, and Region 2024-2032 |
2023年全球黏稠補充劑市場規模達到45億美元。展望未來, IMARC Group預計到2032年市場規模將達到87億美元,2024-2032年複合年成長率(CAGR)為7.42%。骨質疏鬆症和骨關節炎(OA)盛行率的增加以及消費者對微創非手術治療的傾向的轉變是推動市場發展的一些關鍵因素。
黏性補充代表一種微創醫療程序,其中將包含被稱為外源性液壓酸(HA)衍生物的凝膠狀流體的關節內注射直接施用到患者的膝關節中。它充當潤滑劑,使骨骼能夠在彼此之間平滑移動,減少炎症,並充當關節負荷的減震器。黏液補充可減少運動過程中的摩擦,幫助滑液產生更多緩衝,消除劇烈疼痛,並增強關節的運動或活動範圍。除此之外,它還能恢復滑液的流變特性,進而產生機械、鎮痛、抗發炎和軟骨保護作用。因此,黏彈性補充被廣泛用於治療膝關節、髖部和手骨關節炎。目前主要有中、低、高分子量。
骨質疏鬆症和骨關節炎(OA)盛行率的增加是推動市場成長的關鍵因素之一。與此一致的是,消費者對微創非手術治療方案的傾向不斷變化,促進了醫療保健領域廣泛採用黏彈性補充劑來治療皮質類固醇和關節疼痛。反過來,這也是另一個主要的成長誘導因素。消費者對非手術治療的多重好處的認知不斷增強,包括無需住院、費用更少、併發症最少以及更好的臨床結果和康復率,進一步影響了這一點。此外,政府的有利措施和各製藥公司為推出新藥和不同給藥途徑而進行的大量投資正在支持市場成長。此外,門診手術中心(ACS)的出現,提供強化治療,解決身體各部位(如關節、韌帶、肌肉、脊椎和神經)的手術和非手術問題,有利於市場成長。此外,開放標籤單注射液壓酸的推出正在推動市場成長。除此之外,有利的醫療保險報銷政策、易患慢性疾病的老年人口不斷增加、慢性殘疾人數不斷增加、主要參與者之間的合作和夥伴關係以及該領域持續的研發活動醫學科學的發展對市場成長產生正面影響。
The global viscosupplementation market size reached US$ 4.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.7 Billion by 2032, exhibiting a growth rate (CAGR) of 7.42% during 2024-2032. The increasing prevalence of osteoporosis and osteoarthritis (OA) and the shifting consumer inclination toward minimally invasive non-surgical treatments represent some of the key factors driving the market.
Viscosupplementation represents a minimally invasive medical procedure wherein intraarticular injection comprising gel-like fluid known as exogenous hydraulic acid (HA) derivatives are directly administered into the knee joints of the patient. It acts as a lubricant, which enables bones to move smoothly over each other, lowers inflammation, and performs as a shock absorber for joint loads. Viscosupplementation reduces the friction during the movements, assists the synovial fluids in creating more cushion, eliminates severe pain, and enhances the range of movements or motions of the joint. Apart from this, it restores the rheological properties of the synovial fluids, which produce mechanical, analgesic, anti-inflammatory, and chondroprotective effects. As a result, viscosupplementation is extensively utilized in the treatment of knee, hip, and hand osteoarthritis. Currently, it is mainly available in intermediate, low, and high molecular weights.
The increasing prevalence of osteoporosis and osteoarthritis (OA) represents one of the key factors driving the market growth. In line with this, the shifting consumer inclination toward the minimally invasive non-surgical treatment options has facilitated the widespread adoption of viscosupplementation in the healthcare sector for corticosteroids and joint pain management. This, in turn, is acting as another major growth-inducing factor. This is further influenced by the growing consumer awareness regarding the multiple benefits of non-surgical treatments, including no hospitalization, fewer expenses, minimal complications, and better clinical outcomes and recovery rates. Additionally, the favorable government initiatives and significant investments by various pharmaceutical companies to launch novel drugs and different routes of administrations is supporting the market growth. Moreover, the emergence of ambulatory surgical centers (ACS) that offer intensive treatment to resolve surgical and non-surgical problems in various body parts, such as joints, ligaments, muscle, spine, and nerves, is favoring the market growth. Furthermore, the introduction of open-label single-injections with hydraulic acid is propelling the market growth. Apart from this, favorable health insurance reimbursement policies, the rising geriatric population, which is susceptible to chronic ailments, increasing number of individuals with chronic disability, collaborations and partnership among the key players, and continuous research and development (R&D) activities in the field of medical sciences are positively impacting the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global viscosupplementation market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on type, age group, distribution channel, application and end use.
Single Injection
Three Injection
Five Injection
The report has also provided a detailed breakup and analysis of viscosupplementation market based on the type. This includes single, three and five injection. According to the report, single injection represented the largest segment.
Adults
Geriatrics
A detailed breakup and analysis of the viscosupplementation market based on the age group has also been provided in the report. This includes adults and geriatric. According to the report, geriatrics accounted for the largest market share.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
The report has also provided a detailed breakup and analysis of viscosupplementation market based on the distribution channel. This includes hospital, retail and online pharmacies. According to the report, hospital pharmacies represented the largest segment.
Knee Osteoarthritis
Hip Osteoarthritis
Hand Osteoarthritis
Others
A detailed breakup and analysis of the viscosupplementation market based on the application has also been provided in the report. This includes knee, hip and hand osteoarthritis. According to the report, knee osteoarthritis accounted for the largest market share.
Hospitals
Orthopedic Clinics
Others
The report has also provided a detailed breakup and analysis of viscosupplementation market based on the end use. This includes hospitals, orthopedic clinics, and others. According to the report, orthopedic clinics represented the largest segment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, the North America was the largest market for viscosupplementation. Some of the factors driving the North America viscosupplementation market included the rising geriatric population and the affordable health insurance reimbursement policies.
The report has also provided a comprehensive analysis of the competitive landscape in the global viscosupplementation market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Anika Therapeutics Inc., Aptissen S.A., Bioventus LLC, Ferring Pharmaceuticals, Fidia Farmaceutici S.p.A., Johnson & Johnson, LG Chem Ltd., OrthogenRx Inc. (Avanos Medical Inc.), Sanofi S.A., Seikagaku Corporation, Virchow Biotech Private Limited, Zimmer Biomet, Zuventus HealthCare Ltd. (Emcure Pharmaceuticals Limited), etc.